A study analyzing data from the DESTINY-Breast12 trial found that trastuzumab deruxtecan (T-DXd) preserved health-related quality of life and neurological function in patients with pretreated HER2-positive advanced or metastatic breast cancer, even those with brain metastases.
SAN ANTONIO — More than half of patients with pretreated HER2-positive advanced or metastatic breast cancer who received the antibody-drug conjugate trastuzumab deruxtecan (T-DXd; Enhertu) had preservation of health-related quality of life (HRQOL) and neurological function at 1 year, even when the cancer had metastasized to brain, an analysis of data from the For 504 patients with or without brain metastases at baseline, estimated deterioration-free rates at 12 months were greater than 50% for
pain scores and for cognitive, emotional, physical, and social functioning scores, reported Nadia Harbeck, MD, PhD, director of the breast center at LMU University Hospital in Munich, Germany, and colleagues. “The findings for HRQOL and neurological function complement the overall clinical efficacy and safety profile of T-DXd in patients with HER2+ metastatic breast cancer, irrespective of the presence of stable or active brain metastases, and further support T-DXd as a valuable treatment option in this population,” they wrote in a scientific poster presented at the “We’re always worried about cognitive function in our patients with brain metastases, and we see that the cognitive function is well preserved in these patients with brain metastases compared to no baseline brain metastases,” commented Andrew J. Brenner, MD, PhD, from the Mays Cancer Center at UT Health San Antonio, who discussed the findings in a poster spotlight session. DESTINY-Breast12 is a phase 3b/4 open-label, multicenter international study evaluating the efficacy and safety of T-DXd in patients with breast tumors expressing high levels of HER2, with or without brain metastases, who had experienced disease progression on anti-HER2-based regimens and who had received no more than two prior lines of therapy in the metastatic setting (with the exception of tucatinib
HER2-POSITIVE BREAST CANCER TRASTUZUMAB DERUXTECAN QUALITY OF LIFE NEUROLOGICAL FUNCTION BRAIN METASTASES
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
After 10 Years, High School DxD Is Getting a New MangaKolt Day is a computer science student and hobbyist writer who is bringing their brand of criticism and insight to ScreenRant. Outside of media criticism, they have a particular interest in philosophy, especially Nietzsche, Derrida, and Foucault.
Read more »
Trastuzumab Deruxtecan Shows Promise for HR+/HER2-Low/Ultra-Low Metastatic Breast CancerA new analysis of the DESTINY-Breast06 trial highlights the significant clinical benefits of trastuzumab deruxtecan (T-DXd) for patients with hormone receptor-positive (HR+), HER2-low or ultra-low metastatic breast cancer, regardless of their time to progression on previous endocrine therapy.
Read more »
FDA Approves Bispecific HER2 Antibody for Biliary Tract CancerZanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.
Read more »
Palbociclib–Endocrine Therapy Combo Outperforms Standard Chemotherapy in HR+/HER2− Metastatic Breast CancerThe Phase 3 PADMA trial showed that palbociclib plus endocrine therapy doubled progression-free survival compared with chemotherapy in high-risk HR+/HER2− metastatic breast cancer.
Read more »
Nab-Paclitaxel Improves Survival in HR+/HER2– Early Breast Cancer Patients with Low Recurrence ScoresWSG ADAPT trial results show weekly nab-paclitaxel improves disease-free survival in patients with low recurrence scores and poor response to endocrine therapy.
Read more »
Babylonian tablet preserves student's 4,000-year-old geometry mistakeKristina Killgrove is a staff writer at Live Science with a focus on archaeology and paleoanthropology news. Her articles have also appeared in venues such as Forbes, Smithsonian, and Mental Floss. Killgrove holds postgraduate degrees in anthropology and classical archaeology and was formerly a university professor and researcher.
Read more »